Engineered via advanced orthogonal deprotection solid-phase synthesis for targeted metabolic, gastrointestinal, and neuro-regenerative generic applications.
Strategic convergence of national healthcare policies, chronic disease burdens, and API localization mandate transformative supply partnerships.
Indonesia's Badan Pengawas Obat dan Makanan (BPOM) has introduced rigorous scrutiny regarding active pharmaceutical ingredients, mandating comprehensive Drug Master Files (DMF) adhering to ACTD/ICH guidelines. Concurrently, the Indonesian Ministry of Industry actively promotes the TKDN (Tingkat Komponen Dalam Negeri) initiative, pressing national generic drug manufacturers (BUMN like Kimia Farma, Kalbe Farma, and Bio Farma) to secure verifiable, cost-effective raw active substances that comply with domestic finishing and packaging prerequisites.
With more than 19.5 million adult diabetic patients recorded by the International Diabetes Federation (IDF) and increasing cardiovascular challenges across Java, Sumatra, and Bali, the Indonesian healthcare system faces immense budgetary strains under BPJS Kesehatan (JKN program). Next-generation therapeutic peptide APIs—specifically dual-acting GLP-1/GIP receptor agonists, GLP-2 intestinal rehabilitators, and vasoactive peptides—represent indispensable assets to manufacture accessible, high-efficacy generics domestically.
Under Law No. 33/2014 on Halal Product Assurance, pharmaceutical raw materials entering the Indonesian Archipelago are systematically evaluated for porcine-free recombinant organisms, chemical synthesis routes free of cross-contamination, and non-animal-derived raw building blocks. Our synthetic chemical peptide platform eliminates mammalian tissue dependencies, delivering transparent chemical route verification suitable for Indonesian Halal certifications.
Combining proprietary solid-phase peptide synthesis (SPPS), multi-ton annual scalability, and strict impurity elimination mechanisms.
Our Hangzhou synthetic base integrates 1,000L to 3,000L solid-phase reaction vessels, enabling single-batch yields of up to 50 kg of lyophilized therapeutic peptide API to ensure zero disruption in national drug tenders.
Dynamic axial compression industrial prep-HPLC arrays isolate target peptides from deletion sequences, stereoisomers, and truncations, systematically delivering ≥99.0% purity with individual unknown impurities <0.10%.
Comprehensive Open Part / Restricted Part DMF documentation, stability protocols under Zone IVb conditions (30°C/75% RH for tropical Indonesia), and impurity profile elucidations via high-res Orbitrap LC-MS/MS.
Validated -20°C temperature-monitored refrigerated air routes linking Hangzhou directly to Jakarta (CGK), Surabaya (SUB), and Medan (KNO), backed by real-time cellular data loggers and customs priority clearance.
Addressing priority public health sectors through targeted molecular engineering and localized clinical applications.
Diabetes and metabolic syndrome represent primary expenditures in Indonesian hospitals. Peptides such as Mazdutide, Orforglipron, and Cargrilintide provide the foundation for next-generation once-weekly injectable formulations and oral tablets capable of significantly optimizing patient compliance over traditional daily insulins.
Gastroenterology departments across Indonesian tertiary referral facilities (e.g., RSCM Jakarta) treat extensive cases of short bowel syndrome (SBS), radiation enteritis, and inflammatory bowel diseases. Teduglutide acts as an essential GLP-2 analogue restoring mucosal villus architecture and decreasing parenteral nutrition dependence.
Tropical viral fevers and pulmonary infectious sequelae mandate resilient immune therapies. Synthetic Thymosin Alpha 1 and Thymalin provide high-precision cellular immune reconstitution, driving T-cell maturation without generating xenogeneic immune overactivation in vulnerable patients.
A structured, traceable four-phase contract development and manufacturing methodology designed for seamless technology transfer.
Optimizing synthesis pathways using orthogonal pseudo-proline dipeptides, minimized racemization protocols, and continuous solvent recovery models.
Pilot batch transfer to multi-kilogram prep-HPLC chromatography with optimized cut-fractions to eliminate critical D-amino acid isomers.
Controlled cycle freeze-drying guaranteeing residual TFA exchange to acetate, ultra-low moisture (<3.0%), and sub-10 EU/mg endotoxin levels.
Submission of Module 3 Quality documentation formatted explicitly for BPOM e-Registration, stability validation, and analytical method verification.
Essential scientific evaluation criteria to safeguard regulatory approval, clinical efficacy, and formulation integrity.
Crude peptide synthesis retains trifluoroacetic acid (TFA), which can cause tissue irritation and cell toxicity in injectable formulations. Thinheal implements an exhaustive ion exchange process yielding pure acetate or hydrochloride salts with residual TFA <0.25%, meeting stringent US Pharmacopeia and European Pharmacopoeia tolerances.
Peptide racemization during coupling compromises receptor binding affinity. Our analytical quality suite includes Marfey’s reagents and chiral LC-MS/MS mapping to strictly quantify and limit D-enantiomer levels at each amino acid position below 0.1%.
Indonesia operates within Climatic Zone IVb (hot and very humid). Thinheal conducts real-time and accelerated stability programs under 30°C ± 2°C / 75% RH ± 5% RH, ensuring the peptide bulk drug substance sustains potency, color, and reconstitution parameters throughout sea or air transport.
Direct supply from Hangzhou facility with batch-matched CoA, LC-MS spectra, and comprehensive CTD documentation.
Direct answers addressing import protocols, BPOM documentation, cold-chain integrity, and custom synthesis scopes.
Yes. We provide complete ASEAN Common Technical Dossier (ACTD) and ICH CTD Module 3 (Quality) documentation. This includes full characterization (MS, 1D/2D NMR, FT-IR, HPLC), analytical method validation (ICH Q2(R1)), impurities degradation profiling, batch analysis of three consecutive commercial-scale batches, and accelerated/real-time Zone IVb stability studies directly suitable for submission to Badan Pengawas Obat dan Makanan (BPOM).
Therapeutic peptide APIs are lyophilized into high-density amorphous or microcrystalline cakes with residual moisture under 3.0%, vacuum-sealed under an ultra-pure nitrogen atmosphere in USP Type I borosilicate glass vials. Consignments are packaged in calibrated VIP (Vacuum Insulated Panel) dry ice shippers with Bluetooth/cellular temperature logging instruments, ensuring uninterrupted -20°C storage from our Hangzhou factory floor to customs clearance at Soekarno-Hatta (CGK) or Juanda (SUB).
Yes. Our peptide APIs are produced via 100% chemical solid-phase peptide synthesis (SPPS) and solution-phase fragment condensation. We do not utilize porcine-derived reagents, animal enzymes, or bovine sera in synthesis or prep-HPLC purification stages. Our manufacturing facility upholds rigorous cleaning validation protocols to avoid cross-contamination, supporting full traceability required by BPJPH and LPPOM MUI audits.
For custom exploratory synthesis and preclinical formulation testing, our MOQ starts from 1 gram to 10 grams with complete Certificates of Analysis (CoA). For commercial active pharmaceutical ingredients destined for finished dosage formulation, we accommodate batch sizes ranging from 500 grams up to multi-kilogram production campaigns tailored to national tender milestones.
Each release batch undergoes comprehensive quality testing: Reversed-Phase HPLC purity (UV detection at 214nm/220nm), high-resolution ESI-MS or MALDI-TOF identity verification, amino acid analysis (AAA), peptide content calculation, counter-ion determination (acetate/trifluoroacetate by ion chromatography), residual water content (Karl Fischer), residual organic solvents (Headspace GC), bacterial endotoxin (LAL assay, USP <85>), and bioburden screening.
Thin